November 13, 2023
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
November 2, 2023
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
October 11, 2023
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®
August 3, 2023
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights
May 8, 2023
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023
May 4, 2023
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data
February 28, 2023
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
Displaying 1 - 10 of 12
